UBS raised the firm’s price target on Neurocrine (NBIX) to $174 from $152 and keeps a Buy rating on the shares. UBS continues to see steady upside on the stock for remainder of 2025, and tells investors in a research note that for the stock to break from the recent range-bound action, consistently strong uptake on Crenessity is key. The stock is lot less polarized heading into the 2Q25 print, as opposed to 4Q24, UBS argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine initiates Phase 1 study of NBIP-01435
- Neurocrine presents new data analyses from KINECT-HD study
- Neurocrine presents new data on patient-reported improvements with INGREZZA
- Neurocrine names Lewis Choi as Chief Information Officer
- Neurocrine announces new data from Phase 4 KINECT-PRO study